Hypertension in CKD Pregnancy: a Question of Cause and Effect (Cause or Effect? This Is the Question)
详细信息    查看全文
  • 作者:Giorgina Barbara Piccoli ; Gianfranca Cabiddu…
  • 关键词:Preeclampsia ; Pregnancy ; Hypertension ; Chronic kidney disease ; Pregnancy outcomes
  • 刊名:Current Hypertension Reports
  • 出版年:2016
  • 出版时间:April 2016
  • 年:2016
  • 卷:18
  • 期:5
  • 全文大小:1,115 KB
  • 参考文献:1.Nevis IF, Reitsma A, Dominic A, et al. Pregnancy outcomes in women with chronic kidney disease: a systematic review. Clin J Am Soc Nephrol. 2011;6(11):2587–98.CrossRef PubMed PubMedCentral
    2.Piccoli GB, Fassio F, Attini R, et al. Pregnancy in CKD: whom should we follow and why? Nephrol Dial Transplant. 2012;27 Suppl 3:iii111–8.CrossRef PubMed
    3.Williams D, Davison J. Chronic kidney disease in pregnancy. BMJ. 2008;336(7637):211–5.CrossRef PubMed PubMedCentral
    4.Alkhunaizi A, Melamed N, Hladunewich MA. Pregnancy in advanced chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens. 2015;24(3):252–9.CrossRef PubMed
    5.Conrad KP. Mechanisms of renal vasodilation and hyperfiltration during pregnancy. J Soc Gynecol Investig. 2004;11(7):438–48.CrossRef PubMed
    6.Hussein W, Lafayette RA. Renal function in normal and disordered pregnancy. Curr Opin Nephrol Hypertens. 2014;23(1):46–53.CrossRef PubMed PubMedCentral
    7.•
Piccoli GB, Cabiddu G, Attini R, et al. Risk of adverse pregnancy outcomes in women with CKD. J Am Soc Nephrol. 2015;26(8):2011–22. A large prospective cohort study, on over 500 singleton pregnancies, highlighting the risks of adverse pregnancy outcomes, in particular in those early CKD stages often considered as of lesser relevance with respect to pregnancy outcomes.CrossRef PubMed
8.•
Bramham K, Parnell B, Nelson-Piercy C, Seed PT, Poston L, Chappell LC. Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis. BMJ. 2014;348:g2301. A comprehensive systematic review supporting counselling for hypertensive patients in pregnancy.CrossRef PubMed PubMedCentral
9.Hage FG, Mansur SJ, Xing D, Oparil S. Hypertension in women. Kidney Int Suppl (2011). 2013;3(4):352–6.CrossRef
10.•
Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245–54. A very useful review on secondary hypertension; not targeted on pregnancy may be of great help for interpretation of chronic hypertension in pregnant women.CrossRef PubMed
11.•
Gillon TE, Pels A, von Dadelszen P, MacDonell K, Magee LA. Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines. PLoS One. 2014;9(12), e113715. An interesting review, indirectly highlighting the many uncertainties in this field.CrossRef PubMed PubMedCentral
12.Ye C, Ruan Y, Zou L, et al. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: prevalence, risk factors, complications, pregnancy and perinatal outcomes. PLoS One. 2014;9(6), e100180.CrossRef PubMed PubMedCentral
13.Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation. 2014;129(11):1254–61.CrossRef PubMed
14.Committee on Hypertension in Pregnancy. Hypertension in pregnancy. Washington, DC: American College of Obstetricians and Gynecologists; 2013.
15.Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis. 1999;33(5):821–8.CrossRef PubMed
16.Glassock RJ, Winearls C. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol. 2008;3(5):1563–8.CrossRef PubMed PubMedCentral
17.Piccoli GB, Conijn A, Attini R, et al. Pregnancy in chronic kidney disease: need for a common language. J Nephrol. 2011;24(3):282–99.CrossRef PubMed
18.Soveri I, Berg UB, Björk J, et al. Measuring GFR: a systematic review. Am J Kidney Dis. 2014;64(3):411–24.CrossRef PubMed
19.Koetje PM, Spaan JJ, Kooman JP, Spaanderman ME, Peeters LL. Pregnancy reduces the accuracy of the estimated glomerular filtration rate based on Cockroft-Gault and MDRD formulas. Reprod Sci. 2011;18(5):456–62.CrossRef PubMed
20.Alper AB, Yi Y, Webber LS, et al. Estimation of glomerular filtration rate in preeclamptic patients. Am J Perinatol. 2007;24(10):569–74.CrossRef PubMed
21.•Cheung KL, Lafayette RA. Renal physiology of pregnancy. Adv Chronic Kidney Dis. 2013;20(3):209–14. Clear and exhaustive pathophysiological review.CrossRef PubMed PubMedCentral
22.Morken NH, Travlos GS, Wilson RE, Eggesbø M, Longnecker MP. Maternal glomerular filtration rate in pregnancy and fetal size. PLoS One. 2014;9(7), e101897.CrossRef PubMed PubMedCentral
23.Piccoli GB, Attini R, Vigotti FN, et al. Is renal hyperfiltration protective in chronic kidney disease-stage 1 pregnancies? A step forward unravelling the mystery of the effect of stage 1 chronic kidney disease on pregnancy outcomes. Nephrology (Carlton). 2015;20(3):201–8.CrossRef
24.Alsuwaida A, Mousa D, Al-Harbi A, Alghonaim M, Ghareeb S, Alrukhaimi MN. Impact of early chronic kidney disease on maternal and fetal outcomes of pregnancy. J Matern Fetal Neonatal Med. 2011;24(12):1432–6.CrossRef PubMed
25.Clark SM, Dunn HE, Hankins GD. A review of oral labetalol and nifedipine in mild to moderate hypertension in pregnancy. Semin Perinatol. 2015;39(7):548–55.CrossRef PubMed
26.•SMFM Publications Committee. SMFM Statement: benefit of antihypertensive therapy for mild-to-moderate chronic hypertension during pregnancy remains uncertain. Am J Obstet Gynecol. 2015;213(1):3–4. A pivotal paper for chronic hypertension and pregnancy, particularly relevant for the assessment of side effects of “hyper” correction.CrossRef
27.Redman CW. Hypertension in pregnancy: the NICE guidelines. Heart. 2011;97(23):1967–9.CrossRef PubMed
28.Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010;341:c2207.CrossRef PubMed
29.Redman C. Pre-eclampsia: a complex and variable disease. Pregnancy Hypertens. 2014;4(3):241–2.
30.Fisher SJ. Why is placentation abnormal in preeclampsia? Am J Obstet Gynecol. 2015;213(4 Suppl):S115–22.CrossRef PubMed
31.•Redman C. The six stages of pre-eclampsia. Pregnancy Hypertens. 2014;4(3):246. A logic and pathophysiological approach to the development of PE; while it may not explain everything, it may be highly useful for the clinicians and the clinical researchers.PubMed
32.Chappell LC, Enye S, Seed P, Briley AL, Poston L, Shennan AH. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension. 2008;51(4):1002–9.CrossRef PubMed
33.Leeman L, Fontaine P. Hypertensive disorders of pregnancy. Am Fam Physician. 2008;78(1):93–100.PubMed
34.Panel discussion. Hypertension-management of hypertensive disorders of pregnancy according to international guidelines: a panel discussion (case 3: superimposed preeclampsia). Am J Perinatol. 2015. doi:10.​1055/​s-0035-1554844 .
35.Lecarpentier E, Tsatsaris V, Goffinet F, Cabrol D, Sibai B, Haddad B. Risk factors of superimposed preeclampsia in women with essential chronic hypertension treated before pregnancy. PLoS One. 2013;8(5), e62140.CrossRef PubMed PubMedCentral
36.Raymond D, Peterson E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv. 2011;66(8):497–506.CrossRef PubMed
37.Bodnar LM, Simhan HN, Catov JM, et al. Maternal vitamin D status and the risk of mild and severe preeclampsia. Epidemiology. 2014;25(2):207–14.CrossRef PubMed PubMedCentral
38.Steiner N, Weintraub AY, Madi Y, Barski L, Sheiner E. The unfavorable slope from mild preeclampsia through severe preeclampsia, to eclampsia. Pregnancy Hypertens. 2013;3(2):146–50.PubMed
39.•Rana S, Schnettler WT, Powe C, et al. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 2013;32(2):189–201. An interesting approach to the “exceptions”; useful in particular for those implementing biomarkers use in the clinical practice.CrossRef PubMed PubMedCentral
40. http://​www.​acog.​org last accessed December 28th 2015.
41.Piccoli GB, Minelli F, Versino E, et al. Pregnancy in dialysis patients in the new millennium: a systematic review and meta-regression analysis correlating dialysis schedules and pregnancy outcomes. Nephrol Dial Transplant. 2015.
42.Piccoli GB, Conijn A, Consiglio V, et al. Pregnancy in dialysis patients: is the evidence strong enough to lead us to change our counseling policy? Clin J Am Soc Nephrol. 2010;5(1):62–71.CrossRef PubMed PubMedCentral
43.Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal disease. N Engl J Med. 2008;359(8):800–9.CrossRef PubMed
44.Sandvik MK, Hallan S, Svarstad E, Vikse BE. Preeclampsia and prevalence of microalbuminuria 10 years later. Clin J Am Soc Nephrol. 2013;8(7):1126–34.CrossRef PubMed PubMedCentral
45.McDonald SD, Han Z, Walsh MW, Gerstein HC, Devereaux PJ. Kidney disease after preeclampsia: a systematic review and meta-analysis. Am J Kidney Dis. 2010;55(6):1026–39.CrossRef PubMed
46.••Garg AX, Nevis IF, McArthur E, et al. Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med. 2015;372(2):124–33. A paper of great interest not only for clinicans involved in transplant care, but also as a model of the effect of “minor” forms of CKD.CrossRef PubMed PubMedCentral
47.Ibrahim HN, Akkina SK, Leister E, et al. Pregnancy outcomes after kidney donation. Am J Transplant. 2009;9(4):825–34.CrossRef PubMed PubMedCentral
48.Reisaeter AV, Røislien J, Henriksen T, Irgens LM, Hartmann A. Pregnancy and birth after kidney donation: the Norwegian experience. Am J Transplant. 2009;9(4):820–4.CrossRef PubMed
49.Rolfo A, Attini R, Tavassoli E, et al. Is it possible to differentiate chronic kidney disease and preeclampsia by means of new and old biomarkers? A prospective study. Dis Markers. 2015;2015:127083.CrossRef PubMed PubMedCentral
50.Rolfo A, Attini R, Nuzzo AM, et al. Chronic kidney disease may be differentially diagnosed from preeclampsia by serum biomarkers. Kidney Int. 2013;83(1):177–81.CrossRef PubMed
51.Piccoli GB, Gaglioti P, Attini R, et al. Pre-eclampsia or chronic kidney disease? The flow hypothesis. Nephrol Dial Transplant. 2013;28(5):1199–206.CrossRef PubMed
52.•Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374(1):13–22. A paper that may represent a paradigm shift for the use of serum biomarkers in the diagnosis of PE.CrossRef PubMed
53.Seely EW, Solomon CG. Improving the prediction of preeclampsia. N Engl J Med. 2016;374(1):83–4.CrossRef PubMed
54.Judd E, Calhoun DA. Management of hypertension in CKD: beyond the guidelines. Adv Chronic Kidney Dis. 2015;22(2):116–22.CrossRef PubMed PubMedCentral
55.•Al Khaja KA, Sequeira RP, Alkhaja AK, Damanhori AH. Drug treatment of hypertension in pregnancy: a critical review of adult guideline recommendations. J Hypertens. 2014;32(3):454–63. A useful, extensive and critical review of old and new drugs.CrossRef PubMed
56.•Hussain A, Karovitch A, Carson MP. Blood pressure goals and treatment in pregnant patients with chronic kidney disease. Adv Chronic Kidney Dis. 2015;22(2):165–9. An important update on one of the most controversial issues in hypertensive pregnancies.CrossRef PubMed
57.Piccoli GB, Cabiddu G, Attini R, et al. Pregnancy in chronic kidney disease: questions and answers in a changing panorama. Best Pract Res Clin Obstet Gynaecol. 2015;29(5):625–42.CrossRef PubMed
58.Brown CM, Garovic VD. Drug treatment of hypertension in pregnancy. Drugs. 2014;74(3):283–96.CrossRef PubMed PubMedCentral
59.Podymow T, August P. Antihypertensive drugs in pregnancy. Semin Nephrol. 2011;31(1):70–85.CrossRef PubMed
60.Easterling TR. Pharmacological management of hypertension in pregnancy. Semin Perinatol. 2014;38(8):487–95.CrossRef PubMed PubMedCentral
61.Holm G. Immunological side-effects of antihypertensive drugs. Acta Med Scand Suppl. 1979;628:85–8.PubMed
62.Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301(1):99–105.CrossRef PubMed
63.Gatault P, Genee O, Legras A, Garot D, Mercier E, Fichet J. Calcium-channel blockers: an increasing cause of pulmonary edema during tocolytic therapy. Int J Cardiol. 2008;130(3):e123–4.CrossRef PubMed
64.Nassar AH, Ghazeeri G, Usta IM. Nifedipine-associated pulmonary complications in pregnancy. Int J Gynaecol Obstet. 2007;97(2):148–9.CrossRef PubMed
65.Sirker A, Missouris CG, MacGregor GA. Dihydropyridine calcium channel blockers and peripheral side effects. J Hum Hypertens. 2001;15(10):745–6.CrossRef PubMed
66.Weir MR. Incidence of pedal edema formation with dihydropyridine calcium channel blockers: issues and practical significance. J Clin Hypertens (Greenwich). 2003;5(5):330–5.CrossRef
67.MacCarthy EP, Bloomfield SS. Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects. Pharmacotherapy. 1983;3(4):193–219.CrossRef PubMed
68.Xie RH, Guo Y, Krewski D, et al. Association between labetalol use for hypertension in pregnancy and adverse infant outcomes. Eur J Obstet Gynecol Reprod Biol. 2014;175:124–8.CrossRef PubMed
69. www.​fda.​org last accessed January 1st 2016.
70.Munkhaugen J, Lydersen S, Romundstad PR, Widerøe TE, Vikse BE, Hallan S. Kidney function and future risk for adverse pregnancy outcomes: a population-based study from HUNT II, Norway. Nephrol Dial Transplant. 2009;24(12):3744–50.CrossRef PubMed
71.KDIGO. Clinical practice guideline for the evaluation and management of blood pressure in chronic kidney disease. Kidney Int Suppl. 2012;2(5):337–414.CrossRef
72.Taler SJ, Agarwal R, Bakris GL, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD. Am J Kidney Dis. 2013;62(2):201–13.CrossRef PubMed PubMedCentral
73.Upadhyay A, Earley A, Haynes SM, Uhlig K. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154(8):541–8.CrossRef PubMed
74.Kovesdy CP, Bleyer AJ, Molnar MZ, et al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study. Ann Intern Med. 2013;159(4):233–42.CrossRef PubMed PubMedCentral
75.Nicholas SB, Vaziri ND, Norris KC. What should be the blood pressure target for patients with chronic kidney disease? Curr Opin Cardiol. 2013;28(4):439–45.PubMed
76.•Ankumah NA, Cantu J, Jauk V, et al. Risk of adverse pregnancy outcomes in women with mild chronic hypertension before 20 weeks of gestation. Obstet Gynecol. 2014;123(5):966–72. An interesting paper suggesting that the effect of hypertension, even if mild, is relevant and that there is a strong direct relationship between blood pressure levels and outcomes, even in the area of “mild” hypertension.CrossRef PubMed
77.Cicero AF, Degli Esposti D, Immordino V, et al. Independent determinants of maternal and fetal outcomes in a sample of pregnant outpatients with normal blood pressure, chronic hypertension, gestational hypertension, and preeclampsia. J Clin Hypertens (Greenwich). 2015;17(10):777–82.CrossRef
78.Cruz MO, Gao W, Hibbard JU. Obstetrical and perinatal outcomes among women with gestational hypertension, mild preeclampsia, and mild chronic hypertension. Am J Obstet Gynecol. 2011;205(3):260.e1–9.CrossRef
79.Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens. 2015;24(2):131–8.CrossRef PubMed
80.Piccoli GB, Attini R, Vasario E, et al. Pregnancy and chronic kidney disease: a challenge in all CKD stages. Clin J Am Soc Nephrol. 2010;5(5):844–55.CrossRef PubMed PubMedCentral
81.Christianson R, Page EW. Diuretic drugs and pregnancy. Obstet Gynecol. 1976;48(6):647–52.PubMed
82.Hall DR, Odendaal HJ. The addition of a diuretic to anti-hypertensive therapy for early severe hypertension in pregnancy. Int J Gynaecol Obstet. 1998;60(1):63–4.CrossRef PubMed
83.•Campese VM. Pathophysiology of resistant hypertension in chronic kidney disease. Semin Nephrol. 2014;34(5):571–6. Bright and clear, this review analyses old and new issues on resistant hypertension.CrossRef PubMed
84.Glicklich D, Frishman WH. Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists. Drugs. 2015;75(5):473–85.CrossRef PubMed
85.Brater DC. Use of diuretics in cirrhosis and nephrotic syndrome. Semin Nephrol. 1999;19(6):575–80.PubMed
86.Mathen S, Venning M, Gillham J. Outpatient management of Gitelman's syndrome in pregnancy. BMJ Case Rep. 2013;2013.
87.Kitsios GD, Mascari P, Ettunsi R, Gray AW. Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. J Crit Care. 2014;29(2):253–9.CrossRef PubMed
88.Duffy M, Jain S, Harrell N, Kothari N, Reddi AS. Albumin and furosemide combination for management of edema in nephrotic syndrome: a review of clinical studies. Cells. 2015;4(4):622–30.CrossRef PubMed PubMedCentral
89.Rascher W, Tulassay T, Seyberth HW, Himbert U, Lang U, Schärer K. Diuretic and hormonal responses to head-out water immersion in nephrotic syndrome. J Pediatr. 1986;109(4):609–14.CrossRef PubMed
90.Kent T, Gregor J, Deardorff L, Katz V. Edema of pregnancy: a comparison of water aerobics and static immersion. Obstet Gynecol. 1999;94(5 Pt 1):726–9.PubMed
91.Katz VL, Ryder RM, Cefalo RC, Carmichael SC, Goolsby R. A comparison of bed rest and immersion for treating the edema of pregnancy. Obstet Gynecol. 1990;75(2):147–51.PubMed
92.Pryde PG, Sedman AB, Nugent CE, Barr Jr M. Angiotensin-converting enzyme inhibitor fetopathy. J Am Soc Nephrol. 1993;3:1575–82.PubMed
93.•Nadeem S, Hashmat S, Defreitas MJ, et al. Renin angiotensin system blocker fetopathy: a Midwest Pediatric Nephrology Consortium report. J Pediatr. 2015;167(4):881–5. Interesting paper providing information on extrarenal, lesser known, malformations.CrossRef PubMed
94.Pucci M, Sarween N, Knox E, Lipkin G, Martin U. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits. Expert Rev Clin Pharmacol. 2015;8(2):221–31.CrossRef PubMed
95.Polifka JE. Is there an embryopathy associated with first-trimester exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists? A critical review of the evidence. Birth Defects Res A Clin Mol Teratol. 2012;94(8):576–98.CrossRef PubMed
96.Steer PJ. Maternal hemoglobin concentration and birth weight. Am J Clin Nutr. 2000;71(5 Suppl):1285S–7.PubMed
97.•Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013;61(1):44–56. An important paper on the adverse effects of ESAs, potentially translated to pregnancy.CrossRef PubMed PubMedCentral
98.Vaziri ND. Cardiovascular effects of erythropoietin and anemia correction. Curr Opin Nephrol Hypertens. 2001;10(5):633–7.CrossRef PubMed
99.Kashiwagi M, Breymann C, Huch R, Huch A. Hypertension in a pregnancy with renal anemia after recombinant human erythropoietin (rhEPO) therapy. Arch Gynecol Obstet. 2002;267(1):54–6.CrossRef PubMed
100.Piccoli G, Bontempo S, Mezza E, et al. Sudden development of low tolerance of dialysis in a young female patient. Nephrol Dial Transplant. 2004;19(1):255–7.CrossRef PubMed
101.•Cabiddu G, Castellino S, Gernone G, Kidney and Pregnancy Study Group of Italian Society of Nephrology, et al. Best practices on pregnancy on dialysis: the Italian Study Group on Kidney and Pregnancy. J Nephrol. 2015;28(3):279–88. One of the few (and the only recent one) best practice guidelines for pregnancy and dialysis.CrossRef PubMed
102.Nahum GG, Stanislaw H. Hemoglobin, altitude and birth weight: does maternal anemia during pregnancy influence fetal growth? J Reprod Med. 2004;49(4):297–305.PubMed
  • 作者单位:Giorgina Barbara Piccoli (1) (2)
    Gianfranca Cabiddu (3)
    Rossella Attini (4)
    Silvia Parisi (4)
    Federica Fassio (4)
    Valentina Loi (3)
    Martina Gerbino (5)
    Marilisa Biolcati (4)
    Antonello Pani (3)
    Tullia Todros (4)

    1. SS Nephrology, Department of Clinical and Biological Sciences, University of Torino, Torino, Italy
    2. Nephrologie, Centre Hospitalier Le Mans, Le Mans, France
    3. SCD Nefrologia, AO Brotzu, Piazzale Ricchi, 1, Cagliari, Italy
    4. SCDU Obstetrics, Department of Surgery, Città della salute e della Scienza, Torino, Italy
    5. SS Nephrology, Department of Clinical and Biological Sciences, AOU san Luigi, Regione Gonzole 10, Orbassano, Torino, Italy
  • 刊物主题:Internal Medicine; Cardiology; Metabolic Diseases; Nephrology; Primary Care Medicine; General Practice / Family Medicine;
  • 出版者:Springer US
  • ISSN:1534-3111
  • 文摘
    Chronic kidney disease (CKD) is increasingly encountered in pregnancy, and hypertension is frequently concomitant. In pregnancy, the prevalence of CKD is estimated to be about 3 %, while the prevalence of chronic hypertension is about 5–8 %. The prevalence of hypertension and CKD in pregnancy is unknown. Both are independently related to adverse pregnancy outcomes, and the clinical picture merges with pregnancy-induced hypertension and preeclampsia. Precise risk quantification is not available, but risks linked to CKD stage, hypertension, and proteinuria are probably multiplicative, each at least doubling the rates of preterm and early preterm delivery, small for gestational age babies, and related outcomes. Differential diagnosis (based upon utero-placental flows, fetal growth, and supported by serum biomarkers) is important for clinical management. In the absence of guidelines for hypertension in CKD pregnancies, the ideal blood pressure goal has not been established; we support a tailored approach, depending on compliance, baseline control, and CKD stages, with strict blood pressure monitoring. The choice of antihypertensive drugs and the use of diuretics and of erythropoiesis-stimulating agents (ESAs) are still open questions which only future studies may clarify.

    © 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

    地址:北京市海淀区学院路29号 邮编:100083

    电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700